AgeneBio Receives $3.4M for Development of Alzheimer's Treatment

AgeneBio of Baltimore has received more than $3 million in new grant funding to further explore treatments for Alzheimer's disease (AD), reports Technical.ly Baltimore . The Alzheimer's Drug Discovery Foundation has allocated $500,000 in grant funding to AgeneBio, while the U.S. National Institutes of Health is supplying $2.9 million through the Small Business Innovation Research program. AgeneBio develops treatments for slowing Mild Cognitive Impairment stemming from AD, and the grant will focus on development of a drug designed to treat overactivity in the hippocampus of the brain. One treatment, GABA-A a5 PAM, is concentrated on specific hippocampal receptors, and AgeneBio seeks to complete work toward the clinical testing stage. "This class of drugs shows great promise, not only for their potential to treat the early symptoms of AD, but also for their ability to address other unmet patient needs in autism and schizophrenia," said AgeneBio CEO Michela Gallagher.